VIM and prostate cancer: Interestingly, a study of metastatic colorectal and prostate cancer patients observed that cell surface vimentin‐positive CTCs that expressed nuclear programmed death‐ligand 1 (PD‐L1) are associated with decreased survival, suggesting that there may exist subpopulations within the mesenchymal CTCs that correlate with clinical parameters (Satelli et al., 2016).